CN1326557C - aPL免疫反应性肽和其缀合物以及治疗aPL抗体－介导的疾病的方法 - Google Patents

aPL免疫反应性肽和其缀合物以及治疗aPL抗体－介导的疾病的方法 Download PDF

Info

Publication number
CN1326557C
CN1326557C CNB96196006XA CN96196006A CN1326557C CN 1326557 C CN1326557 C CN 1326557C CN B96196006X A CNB96196006X A CN B96196006XA CN 96196006 A CN96196006 A CN 96196006A CN 1326557 C CN1326557 C CN 1326557C
Authority
CN
China
Prior art keywords
peptide
apl
compositions
phage
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CNB96196006XA
Other languages
English (en)
Chinese (zh)
Other versions
CN1192153A (zh
Inventor
E·J·维克多利亚
D·M·玛奎司
D·S·琼斯
L·于
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
La Jolla Pharmaceutical Co
Original Assignee
La Jolla Pharmaceutical Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by La Jolla Pharmaceutical Co filed Critical La Jolla Pharmaceutical Co
Publication of CN1192153A publication Critical patent/CN1192153A/zh
Application granted granted Critical
Publication of CN1326557C publication Critical patent/CN1326557C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/10—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C323/11—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and singly-bound oxygen atoms bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C323/12—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and singly-bound oxygen atoms bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6093—Synthetic polymers, e.g. polyethyleneglycol [PEG], Polymers or copolymers of (D) glutamate and (D) lysine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/64—Medicinal preparations containing antigens or antibodies characterised by the architecture of the carrier-antigen complex, e.g. repetition of carrier-antigen units
    • A61K2039/645—Dendrimers; Multiple antigen peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Rheumatology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CNB96196006XA 1995-06-07 1996-06-06 aPL免疫反应性肽和其缀合物以及治疗aPL抗体－介导的疾病的方法 Expired - Fee Related CN1326557C (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/482,651 US5874409A (en) 1995-06-07 1995-06-07 APL immunoreactive peptides, conjugates thereof and methods of treatment for APL antibody-mediated pathologies
US08/482,651 1995-06-07

Publications (2)

Publication Number Publication Date
CN1192153A CN1192153A (zh) 1998-09-02
CN1326557C true CN1326557C (zh) 2007-07-18

Family

ID=23916889

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB96196006XA Expired - Fee Related CN1326557C (zh) 1995-06-07 1996-06-06 aPL免疫反应性肽和其缀合物以及治疗aPL抗体－介导的疾病的方法

Country Status (8)

Country Link
US (2) US5874409A (https=)
EP (1) EP0833648A4 (https=)
JP (1) JPH11507822A (https=)
KR (1) KR19990022712A (https=)
CN (1) CN1326557C (https=)
AU (1) AU711192B2 (https=)
CA (1) CA2223687A1 (https=)
WO (1) WO1996040197A1 (https=)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5268454A (en) * 1991-02-08 1993-12-07 La Jolla Pharmaceutical Company Composition for inducing humoral anergy to an immunogen comprising a t cell epitope-deficient analog of the immunogen conjugated to a nonimmunogenic carrier
KR100361933B1 (ko) * 1993-09-08 2003-02-14 라 졸라 파마슈티칼 컴파니 화학적으로정의된비중합성결합가플랫폼분자및그것의콘주게이트
US5874409A (en) 1995-06-07 1999-02-23 La Jolla Pharmaceutical Company APL immunoreactive peptides, conjugates thereof and methods of treatment for APL antibody-mediated pathologies
US6410775B1 (en) * 1995-06-07 2002-06-25 La Jolla Pharmaceutical Company APL immunoreactive peptides, conjugates thereof and methods of treatment for APL antibody-mediated pathologies
US5817752A (en) * 1996-06-06 1998-10-06 La Jolla Pharmaceutical Company Cyclic polypeptides comprising a thioether linkage and methods for their preparation
KR20000016414A (ko) * 1996-06-06 2000-03-25 와이즈먼 앤드루 Apl 면역반응성 펩티드, 그것의 콘주게이트 및 apl항체-매개병변의 치료방법
US6812327B1 (en) 1996-10-25 2004-11-02 Human Genome Sciences, Inc. Neutrokine-alpha polypeptides
US8212004B2 (en) * 1999-03-02 2012-07-03 Human Genome Sciences, Inc. Neutrokine-alpha fusion proteins
US6858210B1 (en) 1998-06-09 2005-02-22 La Jolla Pharmaceutical Co. Therapeutic and diagnostic domain 1 β2GPI polypeptides and methods of using same
IL126447A (en) * 1998-10-04 2004-09-27 Vascular Biogenics Ltd An immune preparation that confers tolerance in oral administration and its use in the prevention and / or treatment of atherosclerosis
US20050197283A1 (en) * 1998-10-04 2005-09-08 Vascular Biogenics Ltd. Compositions containing beta 2-glycoprotein I for the prevention and/or treatment of vascular disease
US6399578B1 (en) * 1998-12-09 2002-06-04 La Jolla Pharmaceutical Company Conjugates comprising galactose α1,3 galactosyl epitopes and methods of using same
US20010010818A1 (en) * 1998-12-09 2001-08-02 Engle Steven B. Methods and formulations for reducing circulating antibodies
US6458953B1 (en) 1998-12-09 2002-10-01 La Jolla Pharmaceutical Company Valency platform molecules comprising carbamate linkages
CN1762990A (zh) * 1999-06-08 2006-04-26 拉卓拉药物公司 包含氨基氧基的化合价平台分子
AUPQ272699A0 (en) * 1999-09-09 1999-09-30 Unisearch Limited Use of beta2GPI in diagnostic tests for autoimmune diseases
MXPA02005236A (es) * 1999-11-28 2004-03-19 Jolla Pharma Metodos de tratamiento de lupus con base en la afinidad de anticuerpos y metodos de separacion por exclusion y composiciones para el uso de los mismos.
JP2003531588A (ja) 2000-04-11 2003-10-28 ジェネンテック・インコーポレーテッド 多価抗体とその用途
WO2001093914A2 (en) 2000-06-08 2001-12-13 La Jolla Pharmaceutical Company Multivalent platform molecules comprising high molecular weight polyethylene oxide
US7879328B2 (en) * 2000-06-16 2011-02-01 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to B lymphocyte stimulator
PT2281843T (pt) * 2000-06-16 2017-01-02 Human Genome Sciences Inc Anticorpos que se ligam imunoespecificamente a blys
AU2001288301A1 (en) * 2000-08-18 2002-03-04 Human Genome Sciences, Inc. Binding polypeptides and methods based thereon
AU8506601A (en) * 2000-08-18 2002-03-04 Dyax Corp Binding polypeptides for b lymphocyte stimulator protein (blys)
US7319012B2 (en) * 2001-05-30 2008-01-15 Gene Therapy Systems, Inc. Protein arrays and methods and systems for producing the same
EP2423335B1 (en) 2001-06-21 2014-05-14 Dynavax Technologies Corporation Chimeric immunomodulatory compounds and methods of using the same
US20030114405A1 (en) * 2001-08-13 2003-06-19 Linnik Matthew D. Methods of treating systemic lupus erythematosus in individuals having significantly impaired renal function
US7105135B2 (en) * 2001-10-16 2006-09-12 Lockheed Martin Corporation System and method for large scale detection of hazardous materials in the mail or in other objects
DE60222816T2 (de) * 2001-12-03 2008-07-03 Amgen Fremont Inc. Identifizierung hochaffiner moleküle durch screening mit begrenzter verdünnung
US7771951B2 (en) * 2001-12-03 2010-08-10 Amgen Fremont Inc. Antibody categorization based on binding characteristics
CA2469196A1 (en) * 2001-12-03 2003-06-12 Abgenix, Inc. Discovery of therapeutic products
AU2003237870A1 (en) * 2002-06-07 2003-12-22 The Brigham & Women's Hospital, Inc. Method and composition for inhibing or slowing blood coagulation
CN100471486C (zh) 2002-08-12 2009-03-25 戴纳伐克斯技术股份有限公司 免疫调节组合物,其制备方法和使用方法
WO2004060320A2 (en) * 2002-12-27 2004-07-22 La Jolla Pharmaceutical Company Methods of improving health-related quality of life in individuals with systemic lupus erythematosus
US20040258683A1 (en) * 2003-03-30 2004-12-23 Linnik Matthew D. Methods of treating and monitoring systemic lupus erythematosus in individuals
US7771956B2 (en) * 2003-06-30 2010-08-10 Brigham & Women's Hospital, Inc. Method for detecting the presence of a phospholipid
US9062392B2 (en) * 2003-12-30 2015-06-23 Intel Corporation Methods for isolating a peptide methods for identifying a peptide
JP2008514187A (ja) 2004-09-01 2008-05-08 ダイナバックス テクノロジーズ コーポレイション 先天性免疫応答及び自己免疫疾患の阻害法及び阻害用組成物
EP1799709B1 (en) * 2004-09-30 2012-04-04 ORICO Limited Myostatin isoform
CN101146826A (zh) * 2005-01-24 2008-03-19 得克萨斯大学体系董事会 与磷脂酰丝氨酸结合的fc融合构建体及其治疗用途
EP1874334A4 (en) * 2005-04-15 2011-03-30 Vascular Biogenics Ltd COMPOSITIONS WITH BETA 2-GLYCOPROTEIN I-PEPTIDES FOR THE PREVENTION AND / OR TREATMENT OF VASCULAR DISEASES
WO2007142667A2 (en) * 2005-10-13 2007-12-13 Human Genome Sciences, Inc. Treatment of patients with autoantibody positive disease
US9168286B2 (en) * 2005-10-13 2015-10-27 Human Genome Sciences, Inc. Methods and compositions for use in treatment of patients with autoantibody positive disease
WO2007123765A2 (en) * 2006-03-31 2007-11-01 Human Genome Sciences Inc. Neutrokine-alpha and neutrokine-alpha splice variant
CN101522707B (zh) * 2006-08-03 2013-08-28 莫约斯汀医疗有限公司 肌肉生长抑制素拮抗剂
WO2009052148A1 (en) * 2007-10-15 2009-04-23 California Institute Of Technology Functionalized polymers using protected thiols
EP2209896B1 (en) 2007-10-26 2017-03-01 Dynavax Technologies Corporation Methods and compositions for inhibition of immune responses and autoimmunity
WO2010093993A2 (en) * 2009-02-12 2010-08-19 Human Genome Sciences, Inc. Use of b lymphocyte stimulator protein antagonists to promote transplantation tolerance
EP2582398B1 (en) 2010-06-16 2016-04-13 Dynavax Technologies Corporation Methods of treatment using tlr7 and/or tlr9 inhibitors
US9228184B2 (en) 2012-09-29 2016-01-05 Dynavax Technologies Corporation Human toll-like receptor inhibitors and methods of use thereof
CN105353137A (zh) * 2015-12-10 2016-02-24 中国农业科学院饲料研究所 一种快速检测色素苏丹红的方法
JP7117741B2 (ja) * 2018-10-10 2022-08-15 国立大学法人 鹿児島大学 ＩｇＧ結合性ペプチドを含む固相担体及びＩｇＧの分離方法
WO2022197295A1 (en) * 2021-03-17 2022-09-22 Milliken & Company Polymeric colorants with reduced staining

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0498658A2 (en) * 1991-02-08 1992-08-12 La Jolla Pharmaceutical Composition for inducing humoral anergy to an immunogen
US5344758A (en) * 1990-04-06 1994-09-06 Yamasa Shoyu Kabushiki Kaisha Methods for determining anti-phospholipid and anti-cardiolipin antibodies
EP0642798A2 (en) * 1993-09-08 1995-03-15 La Jolla Pharmaceutical Company Chemically-defined non-polymeric valency platform molecules and conjugates thereof
CN1225015A (zh) * 1996-06-06 1999-08-04 拉卓拉药物公司 aPL免疫反应性肽、其缀合物以及aPL抗体介导的疾病的治疗方法

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4191668A (en) 1977-02-03 1980-03-04 Scripps Clinic And Research Foundation Induction of immunological tolerance
US6022544A (en) 1983-01-24 2000-02-08 The John Hopkins University Therapeutic suppression of specific immune responses by administration of oligomeric forms of antigen of controlled chemistry
US5126131A (en) 1983-01-24 1992-06-30 The Johns Hopkins University Therapeutic suppression of specific immune responses by administration of antigen-competitive conjugates.
US5370871A (en) 1983-01-24 1994-12-06 The Johns Hopkins University Therapeutic suppression of specific immune responses by administration of oligomeric forms of antigen of controlled chemistry
US4650675A (en) 1983-08-18 1987-03-17 The Children's Medical Center Corporation Oligonucleotide conjugates
US4751181A (en) 1984-12-31 1988-06-14 Duke University Methods and compositions useful in the diagnosis and treatment of autoimmune diseases
JP2524586B2 (ja) 1985-06-26 1996-08-14 シタス コーポレイション ポリマ−接合を利用する医薬組成物用蛋白質の可溶化
US4904582A (en) 1987-06-11 1990-02-27 Synthetic Genetics Novel amphiphilic nucleic acid conjugates
DE68925899T2 (de) 1988-04-04 1996-10-02 Byron E Anderson Bindung von immunkomplexen durch modifizierte formen von c-reaktiven proteinen
WO1991006006A1 (en) * 1989-10-19 1991-05-02 Yamasa Shoyu Kabushiki Kaisha Carrier for binding antiphospholipid antibody, immunoassay using the same, and kit therefor
US5552391A (en) 1990-01-16 1996-09-03 La Jolla Pharmaceutical Company Chemically-defined non-polymeric valency platform molecules and conjugates thereof
US5162515A (en) 1990-01-16 1992-11-10 La Jolla Pharmaceutical Company Conjugates of biologically stable polymers and polynucleotides for treating systemic lupus erythematosus
JPH04218000A (ja) 1990-02-13 1992-08-07 Kirin Amgen Inc 修飾ポリペプチド
US5498538A (en) * 1990-02-15 1996-03-12 The University Of North Carolina At Chapel Hill Totally synthetic affinity reagents
WO1991015722A1 (de) * 1990-04-10 1991-10-17 Masur, Walter Verfahren zum betreiben einer kompressionswärmepumpe, sowie kompressionswärmepumpe
JPH06503833A (ja) 1990-12-17 1994-04-28 ザ ジョンズ ホプキンス ユニバーシティ 制御された化学のオリゴマー形態の抗原での免疫応答抑制
AU666352B2 (en) * 1992-02-05 1996-02-08 Takao Koike Solid-phase reagent and assay method for measuring antibodies specific to antiphospholipid syndrome
CA2176007A1 (en) 1993-11-16 1995-05-26 Eiji Matsuura Method of assaying antiphospholipid antibody and kit therefor
US5874409A (en) 1995-06-07 1999-02-23 La Jolla Pharmaceutical Company APL immunoreactive peptides, conjugates thereof and methods of treatment for APL antibody-mediated pathologies
KR20000016414A (ko) 1996-06-06 2000-03-25 와이즈먼 앤드루 Apl 면역반응성 펩티드, 그것의 콘주게이트 및 apl항체-매개병변의 치료방법

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5344758A (en) * 1990-04-06 1994-09-06 Yamasa Shoyu Kabushiki Kaisha Methods for determining anti-phospholipid and anti-cardiolipin antibodies
EP0498658A2 (en) * 1991-02-08 1992-08-12 La Jolla Pharmaceutical Composition for inducing humoral anergy to an immunogen
EP0642798A2 (en) * 1993-09-08 1995-03-15 La Jolla Pharmaceutical Company Chemically-defined non-polymeric valency platform molecules and conjugates thereof
CN1225015A (zh) * 1996-06-06 1999-08-04 拉卓拉药物公司 aPL免疫反应性肽、其缀合物以及aPL抗体介导的疾病的治疗方法

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
:"ACTIVITY,DISULPHIDE MAPPING AND STRUCTUAL MODELLING OF THE FIFTH DOMAIN OF HUMA STEINKASSERER ET AL,FEBS LETT,VOL.313,NO.2 1992 *
:"AMINO ACIDSEQUENCE OF THE REGION BETA2-GLYCOPROTEIN 1(GP1) WHICH MEDIATES BINDING O S.A.LAUER ET AL,IMMUNOLOGY,VOL.80.NO.1 1993 *

Also Published As

Publication number Publication date
US5874409A (en) 1999-02-23
EP0833648A1 (en) 1998-04-08
AU6271096A (en) 1996-12-30
JPH11507822A (ja) 1999-07-13
US6207160B1 (en) 2001-03-27
CN1192153A (zh) 1998-09-02
KR19990022712A (ko) 1999-03-25
WO1996040197A1 (en) 1996-12-19
AU711192B2 (en) 1999-10-07
EP0833648A4 (en) 1999-10-13
CA2223687A1 (en) 1996-12-19

Similar Documents

Publication Publication Date Title
CN1326557C (zh) aPL免疫反应性肽和其缀合物以及治疗aPL抗体－介导的疾病的方法
AU734638B2 (en) aPL immunoreactive peptides, conjugates thereof and methods of treatment for aPL antibody-mediated pathologies
WO1996040197A9 (en) aPL IMMUNOREACTIVE PEPTIDES, CONJUGATES THEREOF AND METHODS OF TREATMENT FOR aPL ANTIBODY-MEDIATED PATHOLOGIES
WO1997046251A9 (en) aPL IMMUNOREACTIVE PEPTIDES, CONJUGATES THEREOF AND METHODS OF TREATMENT FOR aPL ANTIBODY-MEDIATED PATHOLOGIES
CN103524603B (zh) 从患有类风湿性关节炎的患者中检测自身抗体的方法、肽和检测试剂盒
US6858210B1 (en) Therapeutic and diagnostic domain 1 β2GPI polypeptides and methods of using same
US6410775B1 (en) APL immunoreactive peptides, conjugates thereof and methods of treatment for APL antibody-mediated pathologies
WO1991008220A1 (en) A method for the stepwise, controlled synthesis of chemical species, particularly peptides, coupled products obtained by the method and the use of these coupled products, e.g. as vaccines
US6455244B1 (en) Methods for the detection of antibodies associated with autoimmune disorders and infectious agents employing immunoretroid peptides derived from antigens associated with said disorders and agents
Kefalides et al. Heterogeneity of antibodies in Goodpasture syndrome reacting with type IV collagen
US7074888B1 (en) Mimotopes and anti-mimotopes of human platelet glycoprotein Ib/IX
EP1106625A1 (en) Rhesus D specific peptide sequences
Verdoliva et al. Antigenicity of topochemically related peptides
EP0955311A2 (en) Peptide vaccine for canine allergy
EP1082340A1 (en) Peptide vaccine for canine allergy
US7592421B1 (en) HLA class II peptide mimics
JP2001523647A (ja) 直鎖状抗原支持単位
AU2004201699A1 (en) Therapeutic and diagnostic domain 1 Beta2GPI polypeptides and methods of using same
JP2003093077A (ja) ｅｒｂＢ−２関連ペプチド
MXPA00012040A (en) THERAPEUTIC AND DIAGNOSTIC DOMAIN 1&bgr;2

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
C19 Lapse of patent right due to non-payment of the annual fee
CF01 Termination of patent right due to non-payment of annual fee